Conference Coverage

Consider antidepressant switch if first one doesn’t work within 2 weeks


 

EXPERT ANALYSIS FROM THE ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES

References

LAS VEGAS – If patients don’t respond to an antidepressant within 2 weeks, it’s probably time to switch them to another antidepressant or think about add-on therapy. If symptoms have gotten worse, however, it’s time to stop the antidepressant altogether, according to Dr. Charles Raison, professor of psychiatry at the University of Arizona in Tucson.

It doesn’t take 6-8 weeks for antidepressants to work; that commonly held notion is “100% wrong,” he said.

Imaging studies show brain activity changes within 2 hours of a single dose, and in trials where antidepressants separate from placebo, they do so in a week or 2 (Arch. Gen. Psychiatry 2006;63:1217-23). “Most of the action is early on,” Dr. Raison said at the annual Perspectives in Rheumatic Diseases conference held by the Global Academy for Medical Education.

Dr. Charles Raison

Dr. Charles Raison

“Monitoring response in the first 2 weeks is essential, because it’s going to tell you whether you’ve got the right” treatment. With any given antidepressant, about 75% of patients will respond, but about 25% will get “much, much worse. If a patient gets worse, stop. You should take that extremely seriously,” he said (Arch. Gen. Psychiatry 2011;68:1227-37).

In general, anxious people and suicidal people don’t do as well on antidepressants. Also, people with a history of childhood neglect, abuse, or trauma respond better to psychotherapy, so it’s worth asking about such issues. It’s also worth asking patients what they want to do, be it pharmaceuticals, psychotherapy, or both. Success is more likely if patients get what they want, Dr. Raison said.

“Pain is a powerful predictor of not doing well,” especially with SSRIs, so “unfortunately, [rheumatologists] deal with populations that are less likely to have a robust response.” Even so, “if you can help people with their pain, you’ll probably help” relieve their depression and help their antidepressant work, he said.

When patients don’t respond after a few weeks, “the first thing most of us do is increase the dose; for SSRIs, the data” indicate it doesn’t work. In one study, for instance, people did just as well on a lower dose as on a higher one, he said (Br. J. Psychiatry 2006;189:309-16).

Up to a quarter of patients, however, will do better if switched to another antidepressant. Some studies suggest staying in the same class of drugs; others suggest trying a different class. For now, which one to pick “depends [mostly] on side effects. There isn’t a best antidepressant; the best one is the one that works in any given patient,” Dr. Raison said (Eur. Neuropsychopharmacol. 2012;22:453-68).

Augmentation is another option, with atypical antipsychotics currently the most popular choice. There’s convincing evidence that they help, but they also have well-known and serious side effects, including extrapyramidal syndromes, metabolic derangements, and weight gain.

There’s also strong evidence for psychotherapy as an adjunct, and good data for lithium and a range of other agents. Whole-body hyperthermia is emerging as a possible depression treatment, as well.

Dr. Raison recommended actively treating nausea, jitteriness, diarrhea, and other short-term SSRI side effects; it makes it more likely that patients will stay on their treatment. Also, anxious patients and those with somatic complaints are more likely to tolerate antidepressants if they are started on subtherapeutic doses, then are titrated slowly up to a recommended dose.

Of all the SSRIs, paroxetine (Paxil) “is the one I most highly recommend you do not use. There’s no evidence it’s better than any of the others,” and it’s the one most likely to cause weight gain, sexual dysfunction, and cardiac issues, he said.

“We don’t know how long you should treat” with antidepressants; “probably at least 6-9 months,” he noted.

Dr. Raison is a consultant for Pamlab, Lilly, and Lundbeck. He is on the speakers bureaus of Pamlab and Sunovion. Global Academy for Medical Education and this news organization are owned by Frontline Medical Communications.

aotto@frontlinemedcom.com

Recommended Reading

Mental health services can be integrated into adolescent primary care
MDedge Psychiatry
Majority of cancer patients with depression untreated; integrated collaborative care found ‘strikingly’ effective
MDedge Psychiatry
Biomarker test may allow immediate diagnosis of concussion
MDedge Psychiatry
Aggression and angry outbursts
MDedge Psychiatry
VIDEO: Access to mental health care a ‘civil rights’ issue
MDedge Psychiatry
Marijuana use continues to rise as perception of risk decreases
MDedge Psychiatry
New approaches urged to address mental illness, addiction
MDedge Psychiatry
Daily cannabis use in teens linked to lower educational attainment, increased suicide risk
MDedge Psychiatry
Long-term benzodiazepine use may contribute to risk of Alzheimer’s
MDedge Psychiatry
After 3-year stumble, new weight-loss drug wins FDA approval
MDedge Psychiatry